Date
Title
Dec 29, 2016

Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application

Nov 23, 2016

Innocoll Holdings plc to Present at the Piper Jaffray Annual Healthcare Conference

Nov 22, 2016

Innocoll Holdings plc Announces Third Quarter 2016 Financial and Operating Results and Provides Corporate Update

Nov 15, 2016

Innocoll to Report Third Quarter 2016 Financial Results and Host Webcast and Conference Call on November 22, 2016

Nov 14, 2016

Innocoll Holdings plc to Present at the Stifel 2016 Healthcare Conference

Nov 03, 2016

Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL

Sep 07, 2016

Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference

Aug 17, 2016

Innocoll Holdings plc Announces Second Quarter 2016 Financial and Operating Results and Provides Corporate Update

Aug 11, 2016

Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016

Jul 06, 2016

Innocoll Holdings plc to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

Jun 23, 2016

Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections

Jun 22, 2016

Innocoll Holdings plc Announces Closing of Public Offering

Jun 16, 2016

Innocoll Holdings plc Announces Pricing of Public Offering of Ordinary Shares

Jun 16, 2016

Innocoll Holdings plc to Present at the JMP Securities Life Sciences Conference

Jun 13, 2016

Innocoll Holdings plc Announces Proposed Public Offering of Ordinary Shares

May 31, 2016

Innocoll Holdings plc Announces First Quarter 2016 Financial and Operating Results and Provides Corporate Update

May 25, 2016

Innocoll Announces XARACOLL® (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief

May 24, 2016

Innocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL® (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief

May 18, 2016

Innocoll to Report First Quarter 2016 Financial Results and Host Webcast and Conference Call on May 31, 2016

Apr 20, 2016

Innocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical Officer

Mar 17, 2016

Innocoll Holdings plc Announces Fourth Quarter and Full-Year 2015 Financial and Operating Results and Provides Corporate Update

Mar 11, 2016

Innocoll to Report Fourth Quarter 2015 Financial Results and Host Webcast and Conference Call on March 17, 2016

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.